Search results
Ocugen completes second cohort dosing in Stargardt trial By Investing.com
Investing.com· 2 days agoThe trial represents a potential breakthrough for patients with this inherited retinal disease,...
Clearside Biomedical stock target cut, maintains Buy rating By Investing.com
Investing.com· 4 days agoOn Monday, Clearside Biomedical (NASDAQ:CLSD) saw its price target adjusted by H.C. Wainwright. The...
A Dietitian Explains the Difference Between Chlorella and Spirulina—Do You Know Which Is Healthier?
Health.com· 2 days agoSpirulina and chlorella are types of microalgae commonly taken in supplement form. They share some...
Best Ads of the Week: Coi Leray kicks it with Foot Locker & Dove decodes mom life with AI
The Drum· 3 days agoThis week, Editora Taverna fought the good fight against gay conversion therapy Brazil, Vivo rallied...
InMed Pharmaceuticals (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results
Digital Journal· 2 days agoInMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on its financial and ...
Meet Dr. Chris Vincent, see the MyEyeDr. difference at Avery Ranch
Community Impact· 5 days agoMyEyeDr. is committed to helping patients live their best lives by providing patients with...
Foundation Fighting Blindness Partners with Preven | Newswise
Newswise· 3 days agoCOLUMBIA, Md., May 15, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, announces ...
Q2 2024 EPS Estimates for Oculis Holding AG Cut by Analyst (NASDAQ:OCS)
ETF DAILY NEWS· 18 hours agoOculis Holding AG (NASDAQ:OCS – Free Report) – Stock analysts at HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Oculis in a research report issued on Monday, May ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoAll three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 6.2%
ETF DAILY NEWS· 2 days agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling ...